Comparison · NCT02908477-deaths
De-escalated Adjuvant Radiation Therapy (DART) vs Standard of Care Treatment (SOC): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. De-escalated Adjuvant Radiation Therapy (DART) vs Standard of Care Treatment (SOC): deaths from any cause. Trial comparisons, record NCT02908477-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02908477-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0147 | 0.00404 | 0.052 | wilson | |
| Risk in group 2 | 0.0978 | 0.0523 | 0.176 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0831 | -0.162 | -0.0243 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.15 | 0.0332 | 0.68 | log | |
| Odds ratio, group 1 over group 2 | 0.138 | 0.029 | 0.653 | log | |
| Number needed to treat, for one fewer death from any cause on De-escalated Adjuvant Radiation Therapy (DART) than on Standard of Care Treatment (SOC) | 12 | 6.19 | 41.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | De-escalated Adjuvant Radiation Therapy (DART) | Docetaxel: 15 mg/m2. Experimental arm only. | 2 | 136 | EG000 |
| Group 2 | Standard of Care Treatment (SOC) | Cisplatin: 40 mg/m2. Standard arm only. | 9 | 92 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse events were collected over 2 years and mortality was collected over 5 years
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
- NCT number
- NCT02908477
- Phases
- PHASE3
- Conditions
- Oropharynx Cancer
- Interventions
- Adjuvant Radiation Therapy, Docetaxel, Cisplatin
- Lead sponsor
- Mayo Clinic
- Results first posted
- 2024-04-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02908477?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02908477-deaths